PolyPid secures FDA Priority Review for D-PLEX100 NDA
PolyPid has received confirmation that the FDA has accepted its New Drug Application for D-PLEX100 and granted the candidate Priority Review, setting a PDUFA target action date of 28 November 2026. The accelerated timeline falls roughly one quarter earlier than the company's previously communicated first-quarter 2027 guidance, and the agency identified no filing review issues during its initial assessment.
D-PLEX100 is designed to prevent surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery. The product uses PolyPid's Kynatrix delivery platform, which provides a sustained local release of doxycycline, a broad-spectrum antibiotic, at the surgical site for up to 30 days. The company says the mechanism could also address infections caused by antibiotic-resistant bacteria, though this claim remains subject to FDA review.
Clinical backing and commercial deal
The NDA is supported by the Phase 3 SHIELD II trial, in which D-PLEX100 met its primary endpoint and showed a 60% relative risk reduction in SSI incidence at the secondary endpoint (p=0.0013) in colorectal procedures involving large incisions. The candidate also holds FDA Breakthrough Therapy Designation for prevention of SSIs in elective colorectal surgery, a designation that reflects the agency's assessment of preliminary evidence showing substantial improvement over existing therapies.
The NDA acceptance has triggered a $15 million milestone payment from Azurity Pharmaceuticals, completing $30 million in combined upfront and near-term milestone payments under an exclusive US and Canada commercialisation partnership announced on 17 July 2026. Should the FDA approve D-PLEX100 by the PDUFA date, Azurity is expected to lead a commercial launch in early 2027.
Chief executive Dikla Czaczkes Akselbrad said the outcome "reflects the quality of our regulatory submission and the rigor of our development program," adding that PolyPid and Azurity are "fully aligned on supporting the Agency's review."
Market context and regulatory read-across
Surgical site infections remain a significant clinical and economic burden, particularly in colorectal procedures, where SSI rates have historically ranged into the double digits despite standard prophylaxis regimens. The category has attracted renewed industry attention as antimicrobial resistance narrows the utility of systemic prophylaxis and payers push for outcome-based metrics in surgical care.
Priority Review status compresses the FDA's standard ten-month review window to approximately six months, a meaningful advantage for a company of PolyPid's size and cash position. The Breakthrough Therapy Designation, granted earlier in development, is a further indicator that FDA reviewers have engaged substantively with the SHIELD II dataset. However, Priority Review does not guarantee approval, and the agency may still request additional information or issue a complete response letter before the November date.
If approved, D-PLEX100 would enter a market where no dedicated, locally delivered antibiotic prophylaxis product is currently approved in the US for this indication, giving PolyPid a potentially clear initial commercial lane. Competitive pressure over the medium term could come from other controlled-release anti-infective platforms in earlier development, as well as from systemic prophylaxis regimens that remain entrenched in surgical protocols across hospital systems.